Kite Pharma (KITE) Posts Q4 Loss of 85c/Share

Kite Pharma (NASDAQ: KITE) reported Q4 EPS of ($0.85), which may not compare with the analyst estimate of ($0.71). Revenue for the quarter came in at $4.89 million versus the consensus estimate of $4.54 million.

For earnings history and earnings-related data on Kite Pharma (KITE) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue
• Thor Industries (THO) Misses Q4 EPS by 13c